News of Note—Neurostimulation player ElectroCore bags $36M; Ethicon slammed with $57M pelvic mesh verdict

News of note

> ElectroCore, which markets a noninvasive vagus nerve stimulation device that treats pain associated with episodic cluster headaches, raised $36 million. SEC filing

> Johnson & Johnson’s Ethicon unit was ordered to pay $57.1 million in a pelvic mesh suit. Philadelphia Inquirer article

> The FDA cleared MyndTec’s functional electric stimulation system for the treatment of patients with upper extremity paralysis. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

Thermo Fisher Scientific has begun early talks to take over Dutch diagnostics maker Qiagen, according to reports.

Atomwise and Velocity Pharmaceutical Development co-founded a company to carry AI-derived drugs through preclinical testing and into takeout deals.

Sera Prognostics has raised $36 million in funding to help commercialize its blood test for assessing the risk of premature births.